PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.68%
EBIT growth above 1.5x CRVO's 8.14%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
22.68%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
22.99%
Net income growth 1.25-1.5x CRVO's 16.56%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
38.32%
EPS growth under 50% of CRVO's 80.04%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
38.32%
Diluted EPS growth under 50% of CRVO's 80.04%. Michael Burry would worry about an eroding competitive position or excessive dilution.
24.80%
Share count expansion well above CRVO's 19.74%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.80%
Diluted share count expanding well above CRVO's 19.74%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.87%
Similar OCF growth to CRVO's 22.78%. Walter Schloss would assume comparable operations or industry factors.
22.60%
FCF growth similar to CRVO's 22.78%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13974.70%
Negative 10Y OCF/share CAGR while CRVO stands at 98.70%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
19.53%
Below 50% of CRVO's 96.32%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
73.45%
3Y OCF/share CAGR at 75-90% of CRVO's 88.89%. Bill Ackman would press for improvements in margin or overhead to catch up.
-5088.50%
Negative 10Y net income/share CAGR while CRVO is at 98.97%. Joel Greenblatt sees a major red flag in long-term profit erosion.
66.11%
Positive 5Y CAGR while CRVO is negative. John Neff might view this as a strong mid-term relative advantage.
78.36%
3Y net income/share CAGR 75-90% of CRVO's 90.92%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
2877.65%
10Y equity/share CAGR above 1.5x CRVO's 103.85%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
75.50%
5Y equity/share CAGR at 50-75% of CRVO's 102.52%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
-75.29%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-36.19%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-16.18%
We cut SG&A while CRVO invests at 10.87%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.